Business Context and Reporting Period
This Form 8-K was filed by SeaStar Medical Holding Corporation on February 6, 2024. The report addresses the Company's compliance status with The Nasdaq Stock Market, LLC listing requirements following previous deficiency notices regarding market value and minimum bid price.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance status rather than financial performance metrics.
Material Changes
- Market Value Rule Compliance: The Company received notification on February 6, 2024, that it has regained compliance with Nasdaq Listing Rule 5550(b)(2) (Market Value Rule), which requires a market value of listed securities of at least $35.0 million.
- Minimum Bid Price Non-Compliance: The Company remains non-compliant with Nasdaq Listing Rule 5550(a)(2) (Minimum Bid Price Rule), as the closing bid price of its Common Stock has remained below $1.00 per share for 30 consecutive business days.
Outlook, Risks, and Management Commentary
- Upcoming Hearing: The Company is scheduled to present its views and a plan to regain compliance with the Minimum Bid Price Rule at a hearing before the Nasdaq Hearings Panel on March 12, 2024.
- Trading Status: Subject to the final written decision by the Panel, the Company's noncompliance with the Minimum Bid Price Rule will not have an immediate effect on the listing or trading of its Common Stock. Trading will continue on the Nasdaq Capital Market under the symbol "ICU."
- Risk: The primary risk is the potential delisting or failure to satisfy continued listing standards if the Company cannot demonstrate a viable plan to meet the Minimum Bid Price Rule.
Investor Verification Checklist
- Verify the outcome of the Nasdaq Hearings Panel scheduled for March 12, 2024.
- Monitor the daily closing bid price of the Common Stock (Symbol: ICU) to assess progress toward the $1.00 threshold.
- Review the Company's specific plan to regain compliance with the Minimum Bid Price Rule once presented to the Panel.
- Check for any subsequent 8-K filings regarding the final written decision from the Nasdaq Hearings Panel.